Evidence Hub

Prevalence of sarcopenia in patients with solid tumors A meta analysis based on 81 814 patients

A. Surov, A. Wienke

JPEN - Journal of Parenteral and Enteral Nutrition, 2022

81,814 participants · 100 citations

Abstract

BACKGROUND

The purpose of the present meta-analysis was to analyze the prevalence of sarcopenia on staging computed tomography (CT) in patients with different malignant solid tumors and in different oncologic settings based on a large sample.

METHODS

MEDLINE, Cochrane, and SCOPUS databases were screened for prevalence of sarcopenia in oncologic patients up to December 2021. Overall, 280 studies met the inclusion criteria. The methodological quality of the involved studies was checked according to the QUADAS instrument. The meta-analysis was undertaken by using RevMan 5.4 software. DerSimonian and Laird random-effects models with inverse-variance weights were used.

RESULTS

The included 280 studies comprised 81814 patients with different tumors. The prevalence of sarcopenia over all included studies was 35.3%. A prevalence of sarcopenia over 50% was identified in esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, sarcomas and thyroid cancer. In head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, renal cell cancer, and ovarian cancer, the prevalence of sarcopenia varied between 35% and 50%. In colorectal cancer, gastric cancer, hepatocellular cancer, and breast cancer, the prevalence of LSMM was below 35%. In curative setting, the prevalence of sarcopenia was 39.6% and in palliative setting, it was 49.2% (p<0.001).

CONCLUSIONS

Sarcopenia is a frequent condition in oncology with a prevalence of 35.3%. The prevalence of sarcopenia is…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free